Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Genesis Lifestyle Medicine vs Revive Meds

Genesis Lifestyle Medicine
Graded #392

Higher grade

vs+0.8000000000000043
Revive Meds
Graded #404

Lower grade

The verdict

Genesis Lifestyle Medicine takes it — 57.7/100 to 56.9/100, but only just.

Genesis Lifestyle Medicine grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Genesis Lifestyle Medicine is a hybrid in-office and telehealth medical spa with 18 clinic locations across 8 states, offering brick-and-mortar accountability uncommon among DTC GLP-1 providers. Revive Meds is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueGenesis Lifestyle Medicine +24
45
21
Dose & formulationRevive Meds +11
53
64
Clinical oversightRevive Meds +2
78
80
Labs & monitoringEven
52
52
FulfillmentRevive Meds +23
67
90
Contract termsGenesis Lifestyle Medicine +2
55
53
Genesis Lifestyle Medicine · left barRevive Meds · right bar

The numbers

MetricGenesis Lifestyle MedicineRevive Meds
WeighScore57.7/10056.9/100
GradeCC
Scorecard rank#392#404
SemaglutideNot disclosed$369/mo (starting dose, compounded)
TirzepatideNot disclosed$459/mo (starting dose, compounded)
Coverage8 statesAll 50 states
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyInjection only

Strengths

  • 18 physical clinics allow in-person consults and injections across 8 states
  • Dual modality — compounded sema/tirz plus brand-name Wegovy and Zepbound on one platform
  • Med spa model lets patients combine weight loss, hormone therapy, and aesthetics
  • Established brand with an 18-location footprint and patient testimonials
  • Telehealth available for remote patients in served states

Where it loses points

  • Pricing not disclosed publicly — gated behind the consultation flow
  • Specific 503A/503B pharmacy partner not named, and the designation not specified
  • No FDA compounded-medication disclaimer visible on the homepage
  • Named medical director not formally disclosed (only a 'Dr. Spinoso' testimonial)
  • Corporate legal entity and governing law not disclosed
Revive Meds

Graded #404 · C

Strengths

  • Offers both compounded semaglutide and dual-agonist tirzepatide, each combined with vitamin B12 (cyanocobalamin) in a single injection
  • Pay-per-order model with no subscription, sign-up fees, or long-term commitment, and free shipping on every order
  • Names its six 503A compounding pharmacies and two prescribing physicians, which is unusually transparent on fulfillment
  • Available in all 50 states and HSA/FSA eligible through a Medical Necessity Letter
  • Prepaying 3 to 12 months cuts the effective cost to as low as $202/mo (semaglutide) or $300/mo (tirzepatide)

Where it loses points

  • Month-to-month pricing is steep: $369/mo semaglutide and $459/mo tirzepatide unless you prepay several months
  • No public price list; pricing appears only after you complete a full health intake and create an account
  • Not LegitScript-certified (no seal displayed on the site)
  • Compounded semaglutide and tirzepatide are not FDA-approved finished products

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard